Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 3/20 | 0.34 |
| ▸ | GLP1R | P43220 | 5/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.32 |
| ▸ | SCTR | P47872 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30037432 | 1.00 | OPRD1 (0.34) | OPRD1GLP1ROPRM1PTGS1GSTK1 | |
| SCHEMBL30455074 | 0.94 | OPRD1 (0.36) | OPRD1GLP1ROPRM1PTGS1GSTK1 | |
| SCHEMBL30666352 | 0.92 | OPRD1 (0.33) | OPRD1OPRM1PTGS1GSTK1 | |
| SCHEMBL30038078 | 0.89 | MME (0.39) | — | |
| SCHEMBL29598237 | 0.89 | MME (0.40) | — | |
| SCHEMBL30627705 | 0.89 | PTGS1 (0.35) | OPRD1OPRM1PTGS1GSTK1 | |
| SCHEMBL29630845 | 0.89 | PTGS1 (0.35) | OPRD1OPRM1PTGS1GSTK1 | |
| SCHEMBL31256943 | 0.89 | OPRM1 (0.42) | OPRD1GLP1ROPRM1 | |
| SCHEMBL29475312 | 0.88 | GLP1R (0.36) | GLP1RPTGS1GSTK1SCTR | |
| SCHEMBL34464905 | 0.88 | PTGS1 (0.36) | OPRD1OPRM1PTGS1GSTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794663-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | Angiochem Inc. (CA) | 2014-10-29 | — | — | EP | disclosed |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2011-11-24 | — | — | US | disclosed |
| WO-2010063124-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | OPRD1 4036/4885GLP1R 56/4885OPRM1 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.